Morningstar valuation, page-39

I could be a chance no interim dividend, more likely a full year div.
Based on the sales of first 2 Q, Axiron is on track at least to beat last year's $US155M sale, adding the exchange rate (lower 4AU/$US) the revenue could be much higher.
They also flagged the expenditure is on similar level of FY2015, means the net cash position should be stronger than 2015.
I couldn't see any reason the Dividend in 2016 lower than last year's 6 Cents.
If we are lucky the Axiron sales trend goes up, it will make Lilly to consider the option of paying raising loyalty plus the potential $50m milestone, or takeover the ACR portfolio as a whole...that could be a interesting question.

Not overly optimistic about the company, would think some potential is there.